Literature DB >> 16926070

Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns.

T Bando1, Y Morikawa, T Komori, E Senba.   

Abstract

Interleukin-31 receptor A (IL-31RA) is a newly identified type I cytokine receptor, that is related to gp130, the common receptor of the interleukin (IL) -6 family cytokines. Recent studies have shown that IL-31RA forms a functional receptor complex for IL-31 together with the beta subunit of oncostatin M receptor (OSMRbeta). However, little is known about the target cells of IL-31 because it remains unclear which types of cells express IL-31RA. In our previous reports, we demonstrated that OSMRbeta is expressed in a subset of small-sized nociceptive neurons of adult dorsal root ganglia (DRGs). In the present study, we investigated the IL-31RA expression in the adult and developing DRGs. From a northern blot analysis and in situ hybridization histochemistry, IL-31RA mRNA was found to be expressed in the adult DRGs. According to reverse-transcriptase polymerase chain reaction, IL-31RA mRNA was detected in the DRGs and trigeminal ganglia, while no expression of IL-31RA mRNA was observed in the CNS. Double immunofluorescence staining revealed IL-31RA to be expressed in a subset of small-sized neurons, all of which colocalized with OSMRbeta. In addition, the expression of IL-31 RA was detected in afferent fibers in the spinal cord and the dermis of the skin. We also found that the developmental expression pattern of IL-31RA was different from that of OSMRbeta; IL31RA-positive neurons in DRGs first appeared at postnatal day (PN) 10 and reached the adult level at PN14, whereas OSMRbeta-positive neurons were observed at PN0 for the first time. We previously demonstrated OSMRbeta-expressing neurons to decrease, however, they were not found to disappear in oncostatin M (OSM) -deficient mice. These findings suggest that IL-31 and OSM may thus have redundant functions in the development of OSMRbeta-expressing neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926070     DOI: 10.1016/j.neuroscience.2006.07.009

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  28 in total

Review 1.  Pruritus in cutaneous T-cell lymphoma: a review.

Authors:  Kristen Ahern; Elaine S Gilmore; Brian Poligone
Journal:  J Am Acad Dermatol       Date:  2012-01-30       Impact factor: 11.527

Review 2.  Interleukin 30 to Interleukin 40.

Authors:  Jovani Catalan-Dibene; Laura L McIntyre; Albert Zlotnik
Journal:  J Interferon Cytokine Res       Date:  2018-10       Impact factor: 2.607

Review 3.  Basic mechanisms of itch.

Authors:  C Potenzieri; B J Undem
Journal:  Clin Exp Allergy       Date:  2011-06-06       Impact factor: 5.018

4.  Itch in dermatomyositis: the role of increased skin interleukin-31.

Authors:  H J Kim; M Zeidi; D Bonciani; S M Pena; J Tiao; S Sahu; V P Werth
Journal:  Br J Dermatol       Date:  2018-06-21       Impact factor: 9.302

Review 5.  Peripheral mechanisms of itch.

Authors:  Benjamin McNeil; Xinzhong Dong
Journal:  Neurosci Bull       Date:  2012-04       Impact factor: 5.203

Review 6.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

Review 7.  Itch mechanisms and circuits.

Authors:  Liang Han; Xinzhong Dong
Journal:  Annu Rev Biophys       Date:  2014       Impact factor: 12.981

8.  Role of stem cell factor and bone marrow-derived fibroblasts in airway remodeling.

Authors:  Vladislav A Dolgachev; Matthew R Ullenbruch; Nicholas W Lukacs; Sem H Phan
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis.

Authors:  Ken Arita; Andrew P South; Günter Hans-Filho; Thais Harumi Sakuma; Joey Lai-Cheong; Suzanne Clements; Maçanori Odashiro; Danilo Nakao Odashiro; Günter Hans-Neto; Nelise Ritter Hans; Maxine V Holder; Balbir S Bhogal; Sian T Hartshorne; Masashi Akiyama; Hiroshi Shimizu; John A McGrath
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

10.  Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.

Authors:  K Kasutani; E Fujii; S Ohyama; H Adachi; M Hasegawa; H Kitamura; N Yamashita
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.